LBA41 Nivolumab (nivo) ± ipilimumab (ipi) in pre-treated patients with advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine tumors (NECs) (GCO-001 NIPINEC) - Archive ouverte HAL Access content directly
Conference Papers Year : 2021

LBA41 Nivolumab (nivo) ± ipilimumab (ipi) in pre-treated patients with advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine tumors (NECs) (GCO-001 NIPINEC)

N. Girard
  • Function : Author
J. Mazieres
  • Function : Author
J. Otto
  • Function : Author
H. Lena
  • Function : Author
C. Lepage
  • Function : Author
T. Egenod
  • Function : Author
D. Smith
  • Function : Author
J. Madelaine
  • Function : Author
L. Gérinière
  • Function : Author
F. El Hajbi
  • Function : Author
A. Ferru
  • Function : Author
C. Clément-Duchêne
  • Function : Author
A. Madroszyk
  • Function : Author
J. Desrame
  • Function : Author
F. Morin
  • Function : Author
A. Langlais
  • Function : Author
P. Michel
  • Function : Author
C. Louvet
  • Function : Author
V. Westeel
  • Function : Author

Dates and versions

hal-04492251 , version 1 (06-03-2024)

Licence

Attribution - NonCommercial - NoDerivatives

Identifiers

Cite

N. Girard, J. Mazieres, J. Otto, H. Lena, C. Lepage, et al.. LBA41 Nivolumab (nivo) ± ipilimumab (ipi) in pre-treated patients with advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine tumors (NECs) (GCO-001 NIPINEC). Abstract Book of the ESMO Congress 2021, 16 – 21 September, Sep 2021, Paris, France. pp.S1318, ⟨10.1016/j.annonc.2021.08.2119⟩. ⟨hal-04492251⟩
5 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More